The Injection Pen is an excellent way to administer a small amount of insulin to a patient. These pens are designed to deliver the exact dosage required. The user should turn the dial of the pen to the correct dose, preferably a low level. The most common sites for injections are the belly, thighs, and buttocks. To use the Injection Pen, the needle should be lined up with the pen. The needle should be held straight while attaching it, as bending it may break the rubber seal or the needle. Once the injection is finished, the pen has an outer cap that can be removed to discard used needles. The injection is then completed by allowing air bubbles to rise from the tip of the needle. To make sure the patient receives the correct dose, the injection pen should be held with the needle pointing upward.
Injection pens are manufactured by several companies. The disposable ones are more popular and have a lower cost. Besides, the Injection Pen has a low risk of infection. Moreover, it has an adjustable needle for better accuracy. The Injection Pen is very convenient for doctors. The safety features of this device are very important. It is safe and can be used by patients of all ages. The device can be easily cleaned before use.
Some of the most common types of Injection Pens are designed to be used in a hospital setting. The Injection Pens can be used to inject a variety of medications. It is widely used in pediatric settings. It can be used for intravenous infusions. Acute and chronic medical conditions such as diabetes are often treated with Injection Pens. They have become an essential part of healthcare. Recently in June 2021, Novo Nordisk Pharma received regulatory approval in Japan for its smart insulin pens, NovoPen Echo Plus and NovoPen 6 as medical devices, which are the first smart insulin pens that are approved in the country.
According to the research by Coherent Market Insights, improving the convenience and ease of administration of parenteral therapeutics has become a common strategy adopted by biotechnology and pharmaceutical industries and is expected to drive growth of injection pen market. Key players aim to introduce novel drug delivery system by targeting end-user flexibility such as fewer handling steps, higher volumes, thinner needles, high viscous formulations, and novel primary containers to accommodate changing injection pen market trends.
The injection pen market is mainly led by 3 companies: Novo Nordisk, Sanofi, and ELI Lilly and Company. Other major players in the injection pen market include Merck & co., Inc., Ypsomed holding AG, Biocorp Production SA, AstraZeneca PLC, F.Hoffman-La Roche Ltd, Becton, Dickinson and Company (BD), Owen Mumford Ltd, Novartis, Pfizer, and Wilhelm Haselmeier GmbH & Co. KG.
For instance, in 2015, Antares Pharma launched Makena subcutaneous auto injector in collaboration with AMAG Pharmaceuticals. This collaboration clubs hydroxyprogesterone caproate injection of Antares Pharma that is used to reduce the risk of preterm birth in women pregnant with a single baby who has a history of singleton spontaneous preterm birth, with QuickShot auto-injector of AMAG Pharmaceuticals to allow rapid subcutaneous self-administration of highly viscous drugs in oil such as testosterone or progesterone and biologics using high spring pressure through a fine gauge needle.
